Phase 3 Trial Testing Pamiparib as Maintenance Therapy for Ovarian Cancer Recruiting Patients in China

Phase 3 Trial Testing Pamiparib as Maintenance Therapy for Ovarian Cancer Recruiting Patients in China
BeiGene has started enrollment in its Phase 3 clinical trial evaluating the investigational PARP inhibitor pamiparib (BGB-290) as a maintenance therapy for ovarian cancer patients who are responding to platinum-based chemotherapy. The trial (NCT03519230) is expected to include 216 adult women with confirmed high-grade serous or endometrioid ovarian cancer, including primary peritoneal and fallopian tube cancer, across 15 to 20 sites in China. Eligible participants must have received at least two prior lines of platinum-based chemotherapy, and achieved a complete or partial response to the last one. Patients in the trial will be randomly assigned to receive oral pamiparib (60 mg) or a placebo twice a day. Researchers will then examine if pamiparib is better than placebo at preventing or delaying disease progression or death. Secondary objectives of the trial include overall survival, objective response rate, and duration of response. For more information, contact BeiGene at [email protected] or visit the trial's registry webpage. “This trial is designed to provide important confirmatory clinical data that could enable registration in the m
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *